인유두종바이러스(HPV) 검사 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for Human Papillomavirus (HPV) testing. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global HPV testing market from 2025 to 2032.

Key Insights:

• HPV Testing Market Size (2025E): US$ 1,400 Mn
• Projected Market Value (2032F): US$ 2,816.3 Mn
• Global Market Growth Rate (CAGR 2025 to 2032):10.5%

HPV Testing Market - Report Scope:

HPV testing is a critical component of cervical cancer screening and prevention programs. These tests detect the presence of high-risk HPV strains associated with the development of cervical cancer. The market caters to hospitals, diagnostic laboratories, and clinics, offering both DNA-based and mRNA-based testing options through various platforms including PCR, hybrid capture, and next-generation sequencing (NGS). The growing awareness about HPV and its link to cervical cancer, coupled with government initiatives promoting routine screening, is significantly propelling market growth. Rising demand for early diagnosis, expanding healthcare infrastructure in emerging regions, and the integration of HPV testing into national screening guidelines further boost market expansion.

Market Growth Drivers:

The global HPV testing market is primarily driven by the increasing prevalence of HPV infections and the rising incidence of cervical cancer worldwide. Favorable government policies and awareness campaigns advocating for routine screening and early detection have improved patient compliance and screening rates. Technological advancements such as the development of self-sampling kits, liquid-based cytology, and high-sensitivity molecular diagnostics are revolutionizing the HPV testing landscape, offering better accuracy and convenience. Furthermore, the growing focus on women's health, especially in low- and middle-income countries, is generating demand for affordable and accessible HPV screening tools. Collaborations between public health organizations and diagnostic companies are also playing a pivotal role in expanding the reach of HPV testing services.

Market Restraints:

Despite positive market momentum, several challenges persist in the HPV testing landscape. High test costs, particularly in developing economies, remain a significant barrier to widespread adoption. Limited access to advanced diagnostic tools and underdeveloped healthcare infrastructure in rural and underserved areas further hamper market penetration. Additionally, cultural barriers, stigma associated with sexual health, and lack of awareness in certain regions hinder patient participation in screening programs. Regulatory hurdles and delays in the approval of new diagnostic technologies also pose challenges for manufacturers and healthcare providers alike. Addressing these issues through education, public health investment, and innovative delivery models is crucial for sustainable market growth.

Market Opportunities:

The HPV testing market presents significant opportunities, particularly with the emergence of home-based testing kits and self-sampling methods that increase convenience and patient participation. Integration of digital health platforms and telemedicine services is further facilitating patient engagement and improving follow-up care. Advances in point-of-care diagnostics and the use of AI-driven diagnostic algorithms are expected to enhance test accuracy and interpretation. The market also stands to benefit from the expansion of HPV testing beyond cervical cancer screening, including applications in head and neck cancer diagnostics. Strategic partnerships, investments in R&D, and customized testing solutions for diverse population groups will be key to unlocking the full market potential and addressing unmet clinical needs.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the HPV testing market globally?
• Which testing technologies and platforms are gaining traction across various regions?
• How are innovations such as self-sampling and AI impacting the HPV diagnostics field?
• Who are the key players in the HPV testing market, and what strategies are they employing to stay competitive?
• What are the emerging trends and future opportunities in the global HPV testing landscape?

Competitive Intelligence and Business Strategy:

Leading players in the global HPV testing market, including QIAGEN N.V., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, and Hologic, Inc., are focused on innovation, geographic expansion, and product portfolio diversification. These companies are investing heavily in the development of high-throughput, user-friendly testing platforms that meet international screening guidelines. Collaborations with national health programs, NGOs, and global health organizations enable these players to enhance accessibility in low-resource settings. Mergers and acquisitions, strategic licensing agreements, and regional distribution partnerships also help strengthen market presence. Companies are increasingly emphasizing awareness-building campaigns and educational initiatives to drive demand and improve health outcomes related to HPV-associated diseases.

Key Companies Profiled:

• QIAGEN N.V.
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Becton, Dickinson and Company
• Seegene, Inc.
• Arbor Vita Corporation
• bioMerieux SA
• Thermo Fisher Scientific, Inc.
• Cepheid (a Danaher Company)
• NURX, Inc.

Human Papillomavirus (HPV) Testing Market Segmentation

By Product

• DNA-based Test
• RNA-based Test

By Application

• Molecular Diagnostics
• Research Use

By End User

• Hospitals
• Clinics
• Diagnostics Centers
• Research Institutes

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Human Papillomavirus Testing Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Product Adoption Analysis
• 3.3. Value Chain Analysis
• 3.4. Key Deals and Mergers
• 3.5. PESTLE Analysis
• 3.6. Porter's Five Force Analysis

4. Global Human Papillomavirus Testing Market Outlook:

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
• 4.3. Global Human Papillomavirus Testing Market Outlook: Product
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 4.3.3.1. DNA-based Test
    • 4.3.3.2. RNA-based Test
  • 4.3.4. Market Attractiveness Analysis: Product
• 4.4. Global Human Papillomavirus Testing Market Outlook: Application
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Application, 2019-2024
  • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 4.4.3.1. Molecular Diagnostics
    • 4.4.3.2. Research Use
  • 4.4.4. Market Attractiveness Analysis: Application
• 4.5. Global Human Papillomavirus Testing Market Outlook: End User
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 4.5.3.1. Hospitals
    • 4.5.3.2. Clinics
    • 4.5.3.3. Diagnostic Centers
    • 4.5.3.4. Research Institutes
  • 4.5.4. Market Attractiveness Analysis: End User

5. Global Human Papillomavirus Testing Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Human Papillomavirus Testing Market Outlook:

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Product
  • 6.2.3. By Application
  • 6.2.4. By End User
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 6.4.1. DNA-based Test
  • 6.4.2. RNA-based Test
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
  • 6.5.1. Molecular Diagnostics
  • 6.5.2. Research Use
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 6.6.1. Hospitals
  • 6.6.2. Clinics
  • 6.6.3. Diagnostic Centers
  • 6.6.4. Research Institutes
• 6.7. Market Attractiveness Analysis

7. Europe Human Papillomavirus Testing Market Outlook:

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Product
  • 7.2.3. By Application
  • 7.2.4. By End User
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 7.4.1. DNA-based Test
  • 7.4.2. RNA-based Test
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
  • 7.5.1. Molecular Diagnostics
  • 7.5.2. Research Use
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 7.6.1. Hospitals
  • 7.6.2. Clinics
  • 7.6.3. Diagnostic Centers
  • 7.6.4. Research Institutes
• 7.7. Market Attractiveness Analysis

8. East Asia Human Papillomavirus Testing Market Outlook:

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Product
  • 8.2.3. By Application
  • 8.2.4. By End User
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 8.4.1. DNA-based Test
  • 8.4.2. RNA-based Test
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
  • 8.5.1. Molecular Diagnostics
  • 8.5.2. Research Use
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 8.6.1. Hospitals
  • 8.6.2. Clinics
  • 8.6.3. Diagnostic Centers
  • 8.6.4. Research Institutes
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Human Papillomavirus Testing Market Outlook:

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Product
  • 9.2.3. By Application
  • 9.2.4. By End User
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 9.4.1. DNA-based Test
  • 9.4.2. RNA-based Test
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
  • 9.5.1. Molecular Diagnostics
  • 9.5.2. Research Use
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 9.6.1. Hospitals
  • 9.6.2. Clinics
  • 9.6.3. Diagnostic Centers
  • 9.6.4. Research Institutes
• 9.7. Market Attractiveness Analysis

10. Latin America Human Papillomavirus Testing Market Outlook:

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Product
  • 10.2.3. By Application
  • 10.2.4. By End User
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 10.4.1. DNA-based Test
  • 10.4.2. RNA-based Test
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
  • 10.5.1. Molecular Diagnostics
  • 10.5.2. Research Use
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 10.6.1. Hospitals
  • 10.6.2. Clinics
  • 10.6.3. Diagnostic Centers
  • 10.6.4. Research Institutes
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Human Papillomavirus Testing Market Outlook:

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Product
  • 11.2.3. By Application
  • 11.2.4. By End User
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 11.4.1. DNA-based Test
  • 11.4.2. RNA-based Test
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
  • 11.5.1. Molecular Diagnostics
  • 11.5.2. Research Use
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 11.6.1. Hospitals
  • 11.6.2. Clinics
  • 11.6.3. Diagnostic Centers
  • 11.6.4. Research Institutes
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. F. Hoffmann-La Roche Ltd.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Agilent Technologies, Inc.
  • 12.3.3. Becton, Dickinson and Company
  • 12.3.4. Qiagen N.V.
  • 12.3.5. Thermo Fisher Scientific Inc.
  • 12.3.6. Abbott Laboratories
  • 12.3.7. Hologic Inc.
  • 12.3.8. Cepheid Inc.
  • 12.3.9. Seegene Inc.
  • 12.3.10. Takara Bio Inc.
  • 12.3.11. DaAn Gene Co., Ltd. of Sun Yat-Sen University
  • 12.3.12. Promega Corporation
  • 12.3.13. Greiner Bio-One International GmbH (Greiner Holding AG)
  • 12.3.14. Enzo Biochem Inc.
  • 12.3.15. Norgen Biotek Corp.
  • 12.3.16. DiagCor Bioscience Inc Ltd
  • 12.3.17. Hybribio Limited
  • 12.3.18. Zytovision GmbH
  • 12.3.19. Arbor Vita Corporation
  • 12.3.20. Medical & Biological Laboratories Co., Ltd
  • 12.3.21. Fujirebio Diagnostics, Inc.

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations